

Making healthcare a right, not a privilege



She would have had a 98% chance of survival if she had not been misdiagnosed.

This is the sad truth behind the case of Stephanie Dickson from Edinburgh, who died in 2013 after a tragic misdiagnosis.

Over 33% of all patients in the world are being incorrectly diagnosed every year*

This problem has steadily increased since studies began in 2003** with no signs of stopping and is growing rapidly in the emerging markets***. It's caused by a healthcare system under high pressure.

AITOPYA is here to relieve that pressure to save lives such as Stephanies'.



Why the problem is not being solved



Healthcare challenges

Pressuring the healthcare system in the emerging markets:

Zero automation

 Health professionals collects and administrates patient data
 manually -> increase in time spent/consultation.

High consumer demand

 Basic primary care has become more common which has created an increased demand to meet a doctor, even for mild health problems
 longer queues.

Medical research

 Health professionals can't keep up with all the updates and new diseases -> lower diagnostic accuracy.



The consequences

For clinics and patients:

- Time consuming consultations.
- Low accessibility
- Continuous decline in health professional/patient ratio because of consumer demand and administrative workload.

HEALTHCARE SYSTEM High pressure!

 The result of all consequences is a lack of productivity, quality and access to healthcare -> slow diagnostics and a low diagnostic accuracy of around 65 %.

Source: Deloitte



The solution

AITOPYA

AITOPYA relieves the pressure in healthcare by empowering patients with a self-diagnostic tool -> diagnostic accuracy.



^{*}Vaccination, treatment of communicable diseases such as pneumonia etc.



AITOPYA – the product

- Instant healthcare AITOPYA, a personalized A.I Doctor available 24/7. Always accessible, no more queues and keep all your health data in one place.
- **Self management** Identify possible diseases by answering questions and inputting your health data. AITOPYA then provides self-care recommendations from the comfort of your home. Chat with health professionals to confirm recommendations in the app or anything health related.
- Connects users to health professionals and guides them to the right one when in need of medical attention. Like a "booking.com" for healthcare. No more "just in case" visits to burden the user or the healthcare system.
- Assisting health professionals by transferring and analyzing user health data that facilitates diagnostic decision making and administration. This reduces the amount of time it takes to consult a patient.
- The unique combination of rule-based data and machine learning ("ML") - contributes to AITOPYAs powerful diagnostic engine that can save lives by giving the correct diagnostic recommendation to users and health professionals at the right time.





Why AITOPYA is the solution

AITOPYA relieves the pressure in healthcare by empowering patients with a self-diagnostic tool

Primary target group* - B2C



M.







Instant healthcare

Your Personal A.I Doctor available 24/7 in your smartphone.

Self-diagnostics and prevention

Monitors your health, provides a health plan and thereby it can prevent diseases. AITOPYA identifies diseases, triages* your health status and guides you to the correct healthcare provider if you really need it.

Chat

Text chat with a partnering doctor (AITOPYA Plus+). Confirm recommendations from the app and discuss anything that is health related.

The product





A new market position in healthcare

Self-assessment.

Connects users with partnering doctors through text chat.

AITOPYA guides you to the health professional that matches your needs and provides them with your data through AITOPYA Pro.

Secondary target group

Partnering with doctors – AITOPYA Pro

A Web service for doctors to receive user data to save them time and improve diagnostic accuracy. It also works as a customer acquisition channel.

















Primary Care

Hospitals/

Specialists

Why now


The digital evolution and healthcare trends are surging

Digital penetration

- Several key factors appear but one big game-changer is internet access, which has increased 1,066 percent since 2000.
- Europe and the U.S are regions with high digital penetration. Sweden has a smartphone penetration (pen.) of 74% (2nd in the world) and internet pen. is >94%.
- Whilst in emerging markets, such as Uganda, has a 16 % smartphone pen. and 44 % internet pen. The difference here is that Uganda (and other emerging markets*) has a growth of almost 400% in digital penetration since 2013.

Emerging markets

With increased access to basic healthcare the emerging markets are now starting to face the same challenges as the rest of the world. Clinics are aggressively seeking solutions to increase quality through diagnostic accuracy and consumers are jumping on the self-management trend.



Market Size Emerging markets is the future



General

- Global health care spending is projected to increase at an annual rate of 5.4% in 2018– 2022. This would be a considerable rise from 2.9% in 2013–2017.
- Total spending is projected to reach USD 10,059 bn in 2022.

Target markets

- Uganda launched in February 2019. Kenya, Nigeria and South Africa in 2020.
- 4 countries = USD **4bn** of the A.I health market.

Market growth

10% of global GDP is spent on health.

With an evergrowing self-management trend in the emerging healthcare markets, demand for instant healthcare from the general public and a healthcare system under pressure the market is in need of an automated self-management solution to collect, store, triage and evaluate patient information.

Addressable market:

- Smart health, USD **510 bn** by 2024
 - The subcategory A.I health stands for USD >102 bn.
 - USD **>24 bn** in Africa and India.

65 % of the market growth is in Asia, Africa and MENA*(emerging markets)!

Source: Worldbank, Deloitte and UBS

Business model

- Primary focus on B2C that will enable a C2B pull towards healthcare providers to generate a rev-share from doctors.
- AITOPYA is an app for anyone to download. There is a free and a Plus+ version.
- AITOPYA Pro* is an app/web service addressed to partnering:
 - Health professionals and clinics
 - Telemedicine partners
 - Insurance and Telco partners
- Think of partnering doctors being a part of a network of clinics within AITOPYA that we can offer our users as a service similar to how Uber offers taxi drivers to their users.

Pricing strategy



Freemium

\$0/month

AITOPYA is free to download and lets the user do check-ups and store their data for free.



Plus+

\$2.5/chat ~50% gross-margin

Chat with AITOPYAs medical team to confirm the recommendation from the app remotely.



Pro*

\$2/transaction

100% gross-margin

AITOPYA Pro (the health professional version).










AITOPYA KPI's

The measurement of AITOPYAs success







>61,000 Totalunique users>18,000 Monthlyactive users

Avg. 80% growth MoM since launch May 2019.











Quality control

Value and safety for our users and partners





Diagnostic accuracy 92%.

Based on >290,000 patients

>450 peer reviewed diagnoses in the AITOPYA medical database.


5 engaged universities

and one NGO. One of the most important factors when consumers choose a healthcare platform to upload their data according to recent studies.*

Time saving

Health professionals saves up to 15% of their time/consultation.





Competitive landscape

	Diagnostic accuracy	Modular A.I	Emerging markets focus	Health care provider	Risk Assessment Algorithm	
	92%🧭	(+)	(+)	Θ	(+)	Don't reinvent the wheel
ada	86%	$\overline{\bigcirc}$	Θ	Θ	\bigcirc	 existing eco system. Not depending on government substitutes.
→ KRY	N/A*	$\overline{\bigcirc}$	Θ	(+)	Θ	 AITOPYA is not a health care provider – easier to scale. AITOPYA scales faster.
♡babylon	85%	\bigcirc	\bigcirc	(+)	\bigcirc	More data -> Stronger A.I.



How to stay ahead of competition and take a greater market share


Funds needed

\$1.2m \$4.4mUSD pre-money

valuation

For what

- Network and expertise
 - Board Members
 - Coaching
 - Industry
- Marketing and sales spend
 - Marketing Campaigns
 - Events/Fairs/Seminars /webinars
- Personnel
 - Sales
 - Marketing
 - Developers
 - CSM/support
 - Finance/Office Admin
 - HR and Legal
- Growth expansion
 - International expansion
 - Product expansion




Expansion strategy

Reaching markets with over two billion people by the end of 2023


Comments

- Medical and technical development in Sweden – no growth, sales or marketing.
- Number of active users is the key to success in keeping a competitive advantage. There are no other regions in the world where you could acquire as many users at the same price.
- Countries of interest need to have a high smartphone and internet penetration.
- Expansion to South America post 2023 is enabled by an initial presence in Spain and Portugal.

User growth



Expansion by 2023



Roadmap and rollout strategy

Technical roadmap

- Plus+ version launch early 2020.
- OATH login possibilities spring 2020.
- Integration towards pharmacies.
- AITOPYA Pro app development.
- AITOPYA Ambassador program** launch.
- M-PESA Payment API in summer.

Technical milestones

- Y/E* target > 600 diagnoses in the A.I disease library.
- Y/E target 95 % diagnostic accuracy.

- Medical device integration (input from blood pressure monitors, glucose monitors, smartwatches and other parameters analyzed by AITOPYA).
- Additional preventional and screening features.
- Develop a subscription model for insurance and long term customers.
- Y/E target > 800 diagnoses in the A.I disease library.
- Y/E target 96 % diagnostic accuracy.
- Y/E target 20 % saved time/health professional.

- Platform structure finalized for integration towards an A.I ecosystem in collaboration with external stakeholders.
- Integrating AITOPYA towards medical imaging databases with X-ray, ultrasound images etc.
- Y/E target > 1 200 diagnoses in the A.I disease library.
- Y/E target 97 % diagnostic accuracy.
- Y/E target 25 % saved time/health professional.

2020

2021

2022

Rollout

Rollout

 Scale up in Uganda and Kenya. Sweden and other western countries serves as references, research and quality indicators, not for scale.







AITOPYA

• Y/E customer target > 150 000 total unique users.

AITOPYA Pro

- Y/E customer target > 30 health professionals.
- Introducing Pharmacies, Insurance and Telecom as potential partners.
- *Y/E = End of year
- **Contact us if you want to know more about the program

- Market entry and expansion in Nigeria and South Africa.
- Pharmacy and Telemedicine integration.



AITOPYA

- Y/E customer target > 1 000 000 total unique users (50 000 Plus+ users).
- Broader marketing and focus on general public.

AITOPYA Pro

- Y/E customer target > 200 health professionals.
- Pharmacies, Y/E customer target > 5.
- Telecom/insurance partner, Y/E customer target > 3.

- Further expansion in Africa
- New regions, market entry in Asia (India) and the Middle-East (U.A.E) in the years to come (Post SeriesA).





AITOPYA

• Y/E customer target > 4 000 000 total unique users (300 000 Plus+ users).

AITOPYA Pro

- Y/E customer target > 1200 health professionals.
- Pharmacies, Y/E customer target > 10.
- Telecom/insurance, Y/E customer target > 8.

Confidential - Do not share



High quality care, everywhere



Affordable and accessible healthcare for anyone, anywhere

AITOPYA is all about providing equal quality healthcare. In the developed countires as well as the emerging markets.



Generation leap - EMR to A.I

AITOPYA lets emerging markets take a generation leap to A.I and avoid the challenges correlated to the electronical medical record systems. The same thing happened in the PC to Smartphone generation leap.



A digitalized health professional

AITOPYA compensates for the low health professional/patient ratio by serving as an A.I Doctor. There are x43 the amount of doctors in the developed countries compared to the emerging markets. This is why AITOPYA is solving a problem that is a need to have – not just nice to have in the emerging markets.



Multi talented team



Academic Backgrounds

- Health professionals, medical students
- Software developers
- Business developers and marketing
- Experienced A.I engineers

Advisory board

- Anders Frisk Bus.dev and market expertise. Started 11 start-ups including Qbrick, 2 in med-tech.
- Jonna Bertfelt >14 years of senior project management experience in health economics in Uganda and Kenya.
- Hatem Fassatoui Previously market insight manager in the emerging markets at Spotify.

Management team



Josef Murad, M.D. CEO | Co-Founder

Monika Petkovic, Chief

Growth Officer








Blaise Ntacyabukura, M.D., CMO





Business KPI's


The measurement of AITOPYAs success*





LTV/CAC (2020)

AITOPYA Pro 2.1x

AITOPYA 1.8x









Financial forecast

Comments

- With an expected market coverage of two billion people in 2023 we expect AITOPYA users to cover 70% of the revenue. Revenue from the app is based on a 10% paying customer base.
- As AITOPYA increases its traction, partners such as telemedicine companies, will see the value in partnering up. The more users we refer to them the more attractive we become.
- AITOPYA Pro will grow as well but not in the same pace due to longer sales processes.
- FTE expected to be 130 by 2023.

CAGR 172% Avg. growth YoY 272%

Profit & loss statement (USD)

	2020	2021	2022	2023
REVENUE				
AITOPYA App				
App, Plus+ version	19,563	109,564	787,420	6,040,948
AITOPYA Pro AITOPYA Licenses	12,940	21,913	157,484	1,208,190
7.17.2.19.7.19.0.19.00	12,7 10	21,710	107, 10 1	1,200,170
TOTAL REVENUES	19,563	131,477	944,904	7,249,137
COST OF GOOD SOLD				
Direct Cost	-17,953	-21,543	-28,007	-39,209
Personnel (Exc. Growth Team)	-306,494	-679,324	-699,703	-720,694
Other cost	-85,329	-105,935	-106,259	-113,413
GROSS MARGIN	-409,775	-806,802	-833,969	-873,316
Gross Margin (%)	-1995%	-514%	12%	88%
Sales, commission, others (Expenses)	-35,483	-191,064	-196,796	-202,700
Marketing	-14,568	-138,901	-710,415	-2,116,800
TOTAL COST	-459,826	-1,136,767	-1,741,180	-3,192,817
EBITA	-371,071	-842,517	-628,620	4,229,007
Margin %	-1897%	-641%	-67%	58%

Our Backers

Comitted VC companies
TWIG, ATOMICO Angel Programme

Private and public Investments

Jellyfish Invest, LiuHolding

\$1,400,000 raised so far



TWIG

YUNCTURE

LIU INVEST






Ownership structure



Name	Type of share	Shareholding	Shareholding %
Josef Murad (co-founder)	А	19,512	21,87%
Matias Murad (co-founder)	А	19,511	21,87%
Jellyfish Invest AB	А	13,384	15%
TWIG AB	А	7,501	8,41%
Mats Westerlund (Angel Inv.)	А	6014	6,74%
242 Holdings AB (Angel Inv.)	А	4,459	5,00%
Anders Frisk (Team member)	А	3,110	3,49%
Abdelraouf Mousa (Angel Inv.)	А	2,587	2,9%
Efraim Jovlunden (Team member)	А	2,353	2,64%
Liu Holding AB (University Holding)	А	2,116	2,37%



Associates and Partners

Universities











Ventures

TWIG



YUNCTURE



LIU INVEST

Others











We're making healthcare a right, not a privilege. AITOPYA is not a luxury, costly platform in healthcare where the sole goal is to save time and to improve diagnostic accuracy. In the end, the vision with AITOPYA is to take one step closer to equal, affordable and accessible quality healthcare. AITOPYA is a necessity if we want to be able to provide quality healthcare on equal ground.

ATOPYA

"Where healthcare is a right, not a privilege"

We're looking for partners, investors, clinics, universities and other facilitators who believes in our vision: To make global healthcare a right, not a privilege by driving the world's transition towards digitalized healthcare solutions.